TARS
Tarsus Pharmaceuticals Inc
76.00$
+2.2%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +598.9% | +111.2% | +47.8% | +17.9% | +38.0% | +18.0% | +31.1% | +15.6% | +27.8% | +6.8% | +7.3% | – | |
| – | +222.5% | +36.0% | +81.6% | +7.9% | +51.9% | +5.8% | +19.7% | +294.3% | -55.6% | -14.0% | +28.9% | – | |
| – | +693.8% | +118.9% | +45.6% | +18.7% | +37.0% | +18.9% | +31.9% | -2.4% | +49.6% | +8.5% | +6.0% | – | |
| – | +9.9% | -9.3% | +2.1% | -1.6% | +39.1% | -14.6% | +8.2% | +4.4% | +10.8% | +23.9% | +38.7% | – | |
| – | +116.6% | -21.5% | +14.0% | -1.5% | +19.2% | +23.1% | +21.2% | +5.5% | +20.3% | +4.4% | +10.5% | – | |
| – | +32.7% | +13.0% | +11.7% | -1.5% | +22.7% | +15.7% | +19.3% | -8.4% | +36.9% | +6.8% | +14.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +15.3% | -0.6% | +114.5% | +9.8% | -6.1% | -4.6% | +1.0% | +1.1% | +4.6% | -3.9% | +1.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -100.9% | – | – | – | – | – | – | – | -214.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.